OncoMed Pharmaceuticals, Inc. (OMED) Forms Descending Triangle Pattern; Strong Momentum for Buyers Coming

September 14, 2018 - By Mary Bollinger

Investors sentiment decreased to 0.96 in 2018 Q2. Its down 0.21, from 1.17 in 2018Q1. It worsened, as 6 investors sold OncoMed Pharmaceuticals, Inc. shares while 17 reduced holdings. 8 funds opened positions while 14 raised stakes. 17.82 million shares or 3.12% less from 18.39 million shares in 2018Q1 were reported.
Hodges Cap Mgmt accumulated 0% or 15,592 shares. Tudor Corporation Et Al stated it has 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Bancshares Of Mellon Corp holds 0% of its portfolio in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 23,539 shares. Morgan Stanley invested in 12,332 shares. Panagora Asset Mngmt reported 30,402 shares or 0% of all its holdings. Connor Clark And Lunn Invest Management Limited invested in 0% or 100,691 shares. Drw Limited Liability Corporation owns 53,740 shares. Manufacturers Life Communication The stated it has 768 shares. Bank & Trust Of Montreal Can stated it has 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Citigroup stated it has 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). D E Shaw accumulated 326,269 shares. Bbr Ptnrs Limited Liability Company accumulated 61,649 shares. 19,555 are held by Citadel Ltd. State Street has invested 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Plante Moran Fincl Advsr Ltd Liability Corporation holds 0% or 380 shares.

Since April 24, 2018, it had 0 insider buys, and 5 insider sales for $58,301 activity. Gurney Austin sold $10,848 worth of stock or 4,051 shares. The insider Li Yvonne sold $13,555. On Tuesday, April 24 Lewicki John A. sold $12,202 worth of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) or 4,557 shares. On Tuesday, April 24 the insider Stagg Robert sold $10,848.

The stock of OncoMed Pharmaceuticals, Inc. (OMED) formed a descending triangle with $3.03 target or 8.00 % above today’s $2.81 share price. The 5 months triangle pattern indicates low risk for the $108.09M company. If the $3.03 price target is reached, the company will be worth $8.65M more.
The descending triangle is in our view more reliable than the ascending one. The descending triangle pattern has break even failure rate for up and down breakouts of 7% and 16%, respectively. The average rise and decline is 47% and 16%. The throwback or so called pullback rates are: 37% and 54%. The stocks meeting their targets is high for this type of breakout: 84% and 54% percent.

The stock decreased 2.52% or $0.0725 during the last trading session, reaching $2.8075. About 88,895 shares traded or 49.62% up from the average. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has declined 39.47% since September 14, 2017 and is downtrending. It has underperformed by 55.09% the S&P500.

Analysts await OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) to report earnings on November, 1. They expect $-0.20 earnings per share, up 28.57 % or $0.08 from last year’s $-0.28 per share. After $-0.10 actual earnings per share reported by OncoMed Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 100.00 % negative EPS growth.

More news for OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) were recently published by: Uk.Finance.Yahoo.com, which released: “Can OncoMed Pharmaceuticals Inc (NASDAQ:OMED) Improve Your Portfolio Returns?” on September 13, 2018. Globenewswire.com‘s article titled: “OncoMed to Present at Two Upcoming Investor Conferences in September” and published on August 29, 2018 is yet another important article.

OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell and immuno-oncology therapeutics. The company has market cap of $108.09 million. The company's product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It currently has negative earnings. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand.

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.